(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Protect Your Speculations with Cd Rates - 2The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- 3Interstellar comet 3I/ATLAS will fly by Earth Friday. Here are the latest images
- 4Poll: 62% of Americans would oppose U.S. military action in Greenland
- 5Instructions to Decide the Best SUV Size for Seniors
- 'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- 10 Activities to Lift Your Consume and Bust Your Stomach
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland?
- The top astronomical discoveries of 2025
- A hospital discharged a woman in labor. This lawmaker wants change.
- 2 bright planets light up April evenings — here's where and when to look
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
